Background
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of the central nervous system (CNS) characterized by the generation of autoantibodies against aquaporin-4 (AQP4), which is the most abundant water channel in the CNS [
1], severe immune-mediated demyelination, and axonal damage that preferentially targets the optic nerves and spinal cord [
2]. Previously regarded as a variant of multiple sclerosis (MS) [
3], NMOSD is now considered an independent disease entity [
2]. Binding of AQP4-IgG or NMO-IgG, which are predominantly IgG
1, to the astrocytic AQP4, causes complement-dependent cytotoxicity and secondary inflammation, with granulocyte and macrophage infiltration, blood-brain barrier disruption, and oligodendrocyte injury [
2].
NMOSD has been frequently associated with dysregulated production of cytokines [
4], which are produced from numerous immune cells, including monocytes [
5]. Among these cytokines, IL-6 is presumed to be critical in the pathogenesis of NMOSD because it is significantly elevated in the serum and cerebrospinal fluid (CSF) of NMOSD patients and promotes AQP4-IgG production by plasmablasts [
6], and blockade of IL-6 in NMOSD patients has been reported to be effective in preventing disease relapse [
6]. One of the proposed mechanisms of IL-6 in disease pathogenesis is that it regulates the transition of leukocyte recruitment. IL-6 shifts neutrophilic infiltrate to the mononuclear cell infiltrate and leads them to participate in disease pathogenesis [
7].
Monocytes are myeloid cells that have multiple immunological functions, including antigen presentation, phagocytosis, and cytokine production. Recent reports suggest that upon activation with LPS, NMOSD monocytes produce higher amounts of inflammatory cytokines such as IL-12, IL-23, and IL-6 compared to healthy controls (HC) [
8]. Also, NMOSD monocytes exhibited increased expression of certain co-stimulatory molecules compared to healthy controls [
9]. However, these data did not show how monocytes react in adaptive immunity, which could be more relevant to study NMOSD pathogenesis where monocytes are recruited to the inflammation site by IFN-γ and activated through CD40/CD40L ligation [
10,
11]. Monocytes possess receptors for the IgG Fc fragment that regulate IgG antibodies in autoimmune diseases [
12]. Among these receptors, CD16, or FcγRIII, is highly expressed in monocytes and used to determine monocyte subset populations and has a higher affinity for IgG
1 than other IgG subtypes [
13]. Monocytes are classified into three subsets based on their CD14 and CD16 expression: classical (CD14
++CD16
+), intermediate (CD14
+CD16
+), and non-classical (CD14
+CD16
++). This classification of monocytes is relatively recent and the individual roles and function of each subset are largely unknown, but CD16 has been linked to susceptibility to autoimmune diseases [
14,
15]. Also, it has been recently published that in Chinese population, non-classical monocyte frequency was higher than HC [
16]. CD16
+ monocytes have been reported to facilitate T cell migration and found around blood vessels in active MS lesions [
17]. Taken together, these data suggest that CD16
+ monocytes could also play an important role in NMOSD.
In this study, we investigated the monocyte inflammatory characteristics, monocyte subset frequency and cytokine production, and cell-surface molecule expression in NMOSD, MS, and healthy controls. We found a remarkable increase in the levels of pro-inflammatory cytokines (TNFα, IL-6, IL-1β, IL-23) and a reciprocal decrease in the levels of an anti-inflammatory cytokine (IL-10) in NMOSD monocytes compared to HC monocytes by IFN-γ or CD40L activation. In addition, increased expression of CD80, ICAM-1, and HLA-DR occurred upon activation with IFN-γ or CD40L, and a constitutively high expression level of CD16 was observed in NMOSD monocytes compared to HC monocytes. Further analysis of monocyte subsets revealed that the high expression of CD16 in NMOSD monocytes, in fact, resulted from an increased frequency of non-classical monocytes. These non-classical monocytes were discovered to be constitutively IL-6-producing cells. Our findings indicate that NMOSD monocytes have increased inflammatory cytokine production, increased inflammatory cell-surface molecule expression, and an increased frequency of a non-classical monocyte subset.
Methods
Patients and healthy controls
Twenty patients with NMOSD fulfilling 2015 diagnostic criteria for NMOSD [
18] and 20 patients with relapsing-remitting MS fulfilling the revised McDonald criteria [
19] were enrolled from the Department of Neurology, National Cancer Center, South Korea. None of the patients had received high-dose steroids within 2 months preceding blood draws. Twenty age- and sex-matched healthy controls were also recruited for blood donation. Demographic and clinical characteristics of three groups and basic information of each patient are summarized in Tables
1 and
2, respectively. Peripheral blood was obtained by venipuncture and processed immediately for monocyte purification as described below.
Table 1
Baseline and clinical characteristics of the study population
HC | 20 | 33.9 ± 10.7 (23–48) | 16:4 | n/a | n/a | n/a |
MS | 20 | 33.4 ± 8.2 (19–51) | 16:4 | 2.5 | 60.4 ± 42.45 | 0% |
NMOSD | 20 | 36.4 ± 6.2 (28–50) | 16:4 | 2.5 | 102.1 ± 84.10 | 100% |
Table 2
Information on immunosuppressive treatments, sampling date, last relapse date, relapse status, and EDSS score of NMOSD and MS patients
1 | NMOSD | 35 | F | MMF | 60 | 90 | Stable | 2 |
2 | NMOSD | 36 | F | MFF | 850 | 72 | Stable | 1.5 |
3 | NMOSD | 41 | F | PD | 197 | 6 | Stable | 3.5 |
4 | NMOSD | 33 | M | MMF | 1767 | 216 | Stable | 4 |
5 | NMOSD | 30 | F | MMF | 565 | 139 | Stable | 1.5 |
6 | NMOSD | 39 | M | MMF | 203 | 111 | Stable | 7.5 |
7 | NMOSD | 44 | F | AZA | 63 | 8 | Stable | 0 |
8 | NMOSD | 28 | F | RTX | 282 | 130 | Stable | 1 |
9 | NMOSD | 36 | F | PD | 79 | 7 | Stable | 2 |
10 | NMOSD | 30 | F | MMF | 834 | 64 | Stable | 2 |
11 | NMOSD | 50 | F | AZA | 418 | 13 | Stable | 5 |
12 | NMOSD | 36 | F | MMF | 1783 | 266 | Stable | 2 |
13 | NMOSD | 46 | M | RTX | 69 | 15 | Stable | 3 |
14 | NMOSD | 32 | F | AZA | 475 | 113 | Stable | 2 |
15 | NMOSD | 40 | F | MMF | 799 | 235 | Stable | 3 |
16 | NMOSD | 34 | F | PD | 60 | 7 | Stable | 2.5 |
17 | NMOSD | 31 | F | MMF | 817 | 49 | Stable | 2 |
18 | NMOSD | 29 | F | MMF | 1403 | 50 | Stable | 1.5 |
19 | NMOSD | 46 | F | RTX | 1753 | 206 | Stable | 2 |
20 | NMOSD | 33 | M | RTX | 64 | 245 | Stable | 2.5 |
21 | MS | 42 | F | Glatiramer acetate | 71 | 78 | Stable | 3.5 |
22 | MS | 38 | F | Teriflunomide | 87 | 84 | Stable | 4 |
23 | MS | 30 | M | Naïve | 113 | 77 | Stable | 3 |
24 | MS | 27 | F | Interferon-β | 904 | 85 | Stable | 5 |
25 | MS | 35 | F | Interferon-β | 2014 | 161 | Stable | 4 |
26 | MS | 19 | M | Glatiramer acetate | 208 | 29 | Stable | 2 |
27 | MS | 25 | M | Naïve | 60 | 3 | Stable | 2 |
28 | MS | 23 | F | Interferon-β | 405 | 13 | Stable | 3.5 |
29 | MS | 23 | F | Glatiramer acetate | 424 | 13 | Stable | 2 |
30 | MS | 46 | F | Interferon-β | 1888 | 76 | Stable | 0 |
31 | MS | 33 | F | Naïve | 60 | 31 | Stable | 2.5 |
32 | MS | 31 | F | Interferon-β | 284 | 18 | Stable | 2.5 |
33 | MS | 51 | F | Interferon-β | 872 | 121 | Stable | 2.5 |
34 | MS | 34 | F | Interferon-β | 739 | 35 | Stable | 0 |
35 | MS | 34 | M | Interferon-β | 225 | 25 | Stable | 2 |
36 | MS | 26 | F | Interferon-β | 206 | 40 | Stable | 0 |
37 | MS | 44 | F | Interferon-β | 191 | 10 | Stable | 0 |
38 | MS | 36 | F | Interferon-β | 1508 | 151 | Stable | 1.5 |
39 | MS | 36 | F | Interferon-β | 519 | 43 | Stable | 3.5 |
40 | MS | 34 | F | Interferon-β | 840 | 115 | Stable | 2 |
PBMC and monocyte isolation and culture
Human peripheral blood mononuclear cells (PBMCs) were obtained using a Ficoll density gradient (GE Healthcare, Pasching, Austria) of buffy coats from healthy donors, NMOSD, and MS patients. Monocytes were purified using a CD14+ magnetic separation system (MACS, Miltenyi Biotec, Sunnyvale, CA, USA). The purity and viability of purified cells were assessed by flow cytometry and PI staining, respectively. All monocyte and PBMC cultures were performed in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum (HyClone Laboratories, Logan, UT, USA) and 1% penicillin/streptomycin (GE Healthcare, Pasching, Austria).
For cytokine production and surface molecule analysis, CD14+ purified monocytes (5.0 × 105 cells/mL) were incubated for 24 h at 37 °C in complete medium. Monocytes were left unstimulated or were stimulated with recombinant human IFN-γ (100 ng/mL, R&D systems, Minneapolis, MN, USA), or recombinant human CD40L (1.0 μg/mL, Enzo Life Sciences, Farmingdale, NY, USA) or both, to mimic encounters with activated T cells. Supernatants were collected for cytokine detection, and cells were detached for flow cytometry analysis. For ICS, CD14+ purified monocytes (5 × 106 cells/mL) were cultured in complete medium, with or without CD40L, for 6 h.
Cytokine detection in monocyte cultured media
The supernatant from CD14+ monocytes cultured media were collected and stored at − 80 °C before use. Cytokine measurement was performed within 4 weeks after the collection of monocytes cultured media and aliquoted to appropriate amounts to avoid repeated freeze/thaw cycles. For measurement of cytokines, standard ELISA kits for IL-10, IL-6, IL-1β, TNFα (all from BioLegend, San Diego, CA, USA), and IL-23 (eBioscience, Vienna, Austria) were purchased and used according to the manufacturer’s instructions.
Flow cytometry assays
Purified CD14+ monocytes cultured for 24 h, with or without stimulation, were labeled with primary antibodies directed against human CD80, CD86, HLA-DR, ICAM-1, or CD16 (all from BD Biosciences, San Jose, CA, USA). For ex vivo staining of inflammatory surface molecules, PBMCs were stained with CD3, CD14, CD16, CD56, CD66b, CD80, CD86, HLA-DR, and ICAM-1. For gating of the three monocyte subsets, we used a fixed set of CD14, CD16, CD3, CD19, CD56, and CD66b (all from BD Biosciences) on PBMCs for negative selection. For intracellular cytokine staining (ICS), PBMCs and monocytes were isolated using a MACS pan-monocyte isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and were incubated with Bredfeldin A (GolgiPlug; 1 μg/mL; BD Biosciences) and CD40L for 6 h. After being stained for surface markers, cells were fixed and made permeable according to the manufacturer’s instructions (BD Biosciences). IL-6, IL-10, TNFα, and IL-1β antibodies against cytokines were from BD Biosciences and IL-23 from Biolegend (San Diego, CA, USA). The appropriate Ig isotypes were included as negative controls. Data was acquired using a FACSVerse (BD Biosciences) and were analyzed with Flowjo software (Treestar, Ashland, OR, USA).
SPADE analysis
Spanning-tree Progression Analysis of Density-normalized Events (SPADE) is an automated clustering algorithm to confirm manual gating [
20]. SPADE analyzes raw flow cytometry data to agglomerate different types of surface molecules into clusters, which allows for easy visualization of rare events. To implement this analysis, we fixed the default settings of 100 nodes and 5 × 10
4 cells per sample.
AQP4-IgG assay
The AQP4-IgG serostatus was confirmed by an in-house cell-based assay using the M23-AQP4-transfected Human Embryonic Kidney 293 (HEK-293) cell line, generated by an internal ribosome entry site (IRES) vector, as previously reported [
21].
Statistical analysis
Data are presented as mean ± standard error of mean (SEM). Prism software was used for unpaired one-way or two-way analysis of variance to assess significance between groups, and Dunnett’s multiple comparison was performed. A p value of less than 0.05 was considered statistically significant and designated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
Discussion
An increasing interest in the role of monocytes in the immune response has yielded findings that monocyte dysregulation is deeply involved in autoimmune diseases such as MS, SLE, and RA. For example, MS monocytes have been reported to be easily activated [
30] and to have increased levels of inflammatory cytokine transcription and translation [
31] and cell-surface molecule expression [
32]. In this study, we hypothesized that NMOSD monocytes are dysregulated in much the same way that MS monocytes are. The data presented here demonstrate that NMOSD monocytes are readily activated and show increased production of inflammatory cytokines, decreased production of IL-10, increased expression of inflammatory surface molecules, and increased frequencies of a non-classical monocyte subset compared to HC monocytes. Interestingly, NMOSD monocytes have an even more inflammatory characteristic in some measures than MS monocytes, which are well-known to be highly inflammatory.
To examine monocyte cytokine production, we evaluated IL-6, TNFα, IL-1β, IL-23, and IL-10 levels. Among these cytokines, IL-6 is reported to play a critical role in the pathogenesis of NMOSD, and furthermore, a treatment targeting IL-6 has shown clinical benefit in NMOSD patients [
33]. Not surprisingly, IL-6 production was found to be the highest in both unstimulated and CD40L-stimulated NMOSD monocytes compared to MS and HC monocytes (Figs.
1a and
5a). The presence of constitutive IL-6-producing non-classical monocytes could explain the reason why NMOSD monocytes produced such high levels of IL-6 under unstimulated condition. Along with IL-6, it has been reported that Th1- and Th17-related pro-inflammatory cytokines are over-expressed in the CSF of NMOSD patients [
34]. TNFα is a Th1-related pro-inflammatory cytokine that is elevated in many autoimmune diseases, and its dysregulation characterizes many autoimmune diseases [
35]. Likewise, IL-1β, which is associated with Th17 differentiation, is also involved in a number of autoimmune diseases, and neutralization of IL-1β in these autoimmune diseases can reduce disease severity [
36]. In NMO-IgG seropositive rats, intra-striatal injection of IL-1β triggered the formation of NMO-like lesions [
37]. In our study, the elevation of TNFα and IL-1β in NMOSD monocytes was observed under stimulated condition. IL-23, produced by myeloid cells, is one of the cytokines that is essential for Th17 differentiation [
38], and Th17 is associated with NMOSD relapse [
39]. We have found that IL-23 production was elevated in NMOSD. In line with the pro-inflammatory cytokines, IL-10, an anti-inflammatory cytokine, had a reciprocally imbalanced production. Previous reports on NMOSD showed that IL-10 level is decreased in the serum [
40].
In MS, cell-surface molecules like co-stimulatory molecules are involved in disease exacerbation, are therapeutic targets [
41], and can influence the age of disease onset [
42]. Inhibition of these co-stimulatory molecules using CTLA-4-Fc in experimental autoimmune encephalomyelitis, an animal model of MS, has been effective in decreasing inflammation and demyelination [
43], but there are few reports on NMOSD. CD80 and CD86 have been reported to be differentially expressed depending on the activation status. CD86 acts as an initial co-stimulatory ligand and is constitutively expressed, whereas CD80 is transiently expressed after activation [
44,
45]. This was also observed in SLE, where CD86 was highly expressed in freshly isolated cells and CD80 was upregulated after culturing for 24 h in media [
45]. In this study, CD86 expression was significantly higher in ex vivo CD16
+ NMOSD and MS monocytes than in HC monocytes (Fig.
5c). In contrast, CD80 was not upregulated in ex vivo
monocytes but showed a significant difference in expression upon stimulation (Fig.
3). These findings therefore agree with those of previous reports on the patterns of CD80 and CD86 expression. Other cell-surface molecules like ICAM-1 and HLA-DR have been shown to be involved in the initiation and propagation of autoimmune diseases [
46,
47]. We found that the expression levels of ICAM-1 and HLA-DR were the highest in NMOSD monocytes both ex vivo (Fig.
5c) and upon stimulation (Fig.
3). These findings concerning the expression of cell-surface molecules also confirm the inflammatory characteristic of NMOSD monocytes.
Monocytes are divided into three subsets based on their expression of CD14 and CD16: CD14
++CD16
+ classical, CD14
+CD16
+ intermediate, and CD14
+CD16
++ non-classical monocytes. Although the individual roles and function of each subset are still being studied, it is assumed that these blood monocyte subsets represent stages in a developmental sequence, with non-classical monocytes being considered as the more mature monocytes [
48]. Several groups have reported increased frequencies of circulating CD16
+ monocytes in various autoimmune diseases [
14,
15]. These CD16
+ monocytes have been shown to actively shape T cell responses by favoring Th17 differentiation [
49] and to facilitate T cell migration [
17]. All these findings suggest that CD16
+ monocytes are involved in the pathogenic processes of autoimmune diseases. Indeed, the frequency of the circulating non-classical monocyte subset was significantly higher in NMOSD than in HC and MS. More importantly, these non-classical NMOSD monocytes constitutively produce IL-6, but this was not the case for non-classical MS and HC monocytes. Upon stimulation with CD40L, NMOSD monocytes produced higher amounts of IL-23 and IL-6 compared to MS and HC monocytes. Taken together, these findings indicate a crucial role for non-classical monocytes in the generation and maintenance of a pathologically relevant Th17 environment in NMOSD patients.
In this study, we used CD40L and/or IFN-γ to mimic encountering with activated T cells. When each of these stimuli was used by themselves, the effects on inflammatory cytokine production and cell-surface molecule upregulation were robust. However, co-treatment of these two stimuli did not produce synergetic effects. One possible explanation of this is that both ligands signal through Jak-STAT pathway components [
50], which would preclude any additive effect, but a further analysis is warranted.
Understanding the adaptive immune system in NMOSD is important to target molecules of immune attack. A series of observation suggest a proinflammatory humoral response in NMOSD [
51]. AQP4-IgG, which is detected in approximately 75~80% of NMOSD patients [
52], has been shown to reproduce the cardinal features of disease pathology [
53‐
56], supporting the direct role of this autoantibody in disease development. Nevertheless, AQP4-IgG alone is not sufficient to provoke the disease. Most likely, AQP4-specific T cells are required in the peripheral immune compartment to help generate the class-switched autoantibodies from B cells, as well as to the development of NMOSD lesions in the CNS. In particular, T helper 17 cells, which can provide B cell help and induce tissue inflammation, may also play a key role in the pathogenesis of NMOSD [
57].
This study has several limitations. First, none of the enrolled NMOSD patients were treatment-naïve. Therefore, the effects of disease-modifying therapies cannot be excluded, although the effect of high-dose steroids was excluded. Nevertheless, it is intriguing that NMOSD monocytes showed a stronger inflammatory phenotype than MS monocytes in some measures despite the use of immunosuppressants (rituximab, RTX; mycophenolate mofetil, MMF; prednisolone, PD; azathioprine, AZT) in NMOSD patients and immunomodulators (glatiramer acetate, interferon-β) in a majority of MS patients. Second, the disease durations for MS (60.4 ± 42.45) and NMOSD (102.1 ± 84.10) were not matched. It is possible that this could affect the data and the monocyte subset frequencies in treatment-naïve or NMOSD patients in an early stage of disease could be different from what we have observed. Third, changes in monocyte dysregulation at relapse have not been evaluated. Lastly, other functions of NMOSD monocytes, like phagocytosis or migration, have not been analyzed. Altogether, these warrant further studies.